Tetrahydrofolates in combination with EGFR-inhibitors
First Claim
1. A method for the treatment of an EGFR-expressing cancer in a patient in need thereof, the method comprising administering to a patient a pharmaceutically active amount of a pharmaceutical composition comprising:
- a) methylene-tetrahydrofolate, andb) cetuximab;
wherein said composition is administered in isolation of 5-fluorouracil and in isolation of analogues, prodrugs and/or metabolites of 5-fluorouracil.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention relates a pharmaceutical composition comprising an EGFR inhibitor and methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate, for use in the treatment of cancer. The methylene-tetrahydrofolate, tetrahydrofolate or methyl-tetrahydrofolate enhances the anticancer efficacy of the EGFR inhibitor. The cancers that may be treated include breast cancer, gastric cancer, gastrointestinal cancer, gall bladder cancer, bile duct cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, head and neck cancer, esophageal cancer, mesothelioma cancer, lung cancer including non-small-cell lung cancer, ovarian cancer, endometrial cancer, cervical cancer, peripheral T-cell lymphoma (PTCL), melanoma, brain tumors, adenocarcinoma, esophageal cancer, and osteosarcoma.
9 Citations
19 Claims
-
1. A method for the treatment of an EGFR-expressing cancer in a patient in need thereof, the method comprising administering to a patient a pharmaceutically active amount of a pharmaceutical composition comprising:
-
a) methylene-tetrahydrofolate, and b) cetuximab; wherein said composition is administered in isolation of 5-fluorouracil and in isolation of analogues, prodrugs and/or metabolites of 5-fluorouracil. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)
-
-
18. A method for inhibiting tumor growth of an EGFR-expressing tumor in a patient in need thereof, the method comprising administering to a patient a pharmaceutically active amount of a pharmaceutical composition comprising methylene-tetrahydrofolate and cetuximab;
- wherein said composition is administered in isolation of 5-fluorouracil and in isolation of analogues, prodrugs and/or metabolites of 5-fluorouracil.
-
19. A method for reducing tumor volume of an EGFR-expressing tumor in a patient in need thereof, the method comprising administering to a patient a pharmaceutically active amount of a pharmaceutical composition comprising methylene-tetrahydrofolate and cetuximab;
- wherein said composition is administered in isolation of 5-fluorouracil and in isolation of analogues, prodrugs and/or metabolites of 5-fluorouracil.
Specification